Chest:COVID-19住院患者的静脉血栓栓塞和出血发生率

2020-11-18 MedSci原创 MedSci原创

在COVID-19住院患者中,VTE的总体估计合并发生率为17.0%。在7.8%的患者中观察到出血事件,需要进行其他研究以明确各种血栓形成事件的重要性,并确定改善患者预后的策略。

个别研究报告2019冠状病毒病(COVID-19)住院患者静脉血栓栓塞(VTE)和出血发生率差异很大。那么,COVID-19住院患者中VTE和出血的发生率是多少?

近日,呼吸领域权威杂志chest上发表了一篇研究文章,在这项系统评价和荟萃分析中,研究人员在2020年1月1日至2020年7月31日之间检索了15个标准和COVID-19特定数据源,且不受语言限制。研究人员使用随机效应荟萃分析汇总了发病率估计值,并使用I2统计量评估了研究的异质性,且使用Begg和Egger的检验评估了发表偏倚。

VTE的合并发生率为17.0%(95%置信区间[CI]为13.4%-20.9%),DVT的合并发生率为12.1%(95%CI为8.4%-16.4%),PE为7.1%(95%CI为5.3%-9.1%),出血为7.8%(95%CI为2.6%-15.3%),严重出血为3.9%(95%CI为1.2%-7.9%)。在亚组荟萃分析中,在ICU患者中,通过筛查评估的VTE发生率较高(33.1% vs 9.8%)。据报道接受中等剂量或全剂量抗凝治疗的患者发生出血的合并估计值最高(21.4%),而在唯一一项评估出血事件的前瞻性研究则最低(2.7%)。

由此可见,在COVID-19住院患者中,VTE的总体估计合并发生率为17.0%。在7.8%的患者中观察到出血事件,需要进行其他研究以明确各种血栓形成事件的重要性,并确定改善患者预后的策略。

原始出处:

David Jiménez.et al.Incidence of venous thromboembolism and bleeding among hospitalized patients with COVID-19: a systematic review and meta-analysis.chest.2020.https://journal.chestnet.org/article/S0012-3692(20)34927-8/fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1698167, encodeId=82b7169816e84, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Nov 19 23:17:40 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929661, encodeId=203a19296610b, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Jun 14 02:17:40 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051621, encodeId=19572051621d9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Dec 23 17:17:40 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955517, encodeId=1d0f195551e14, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 23 17:17:40 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826649, encodeId=a04c182664900, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 03 19:17:40 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901754, encodeId=9eb8901e5494, content=在COVID-19住院患者中,VTE的总体估计合并发生率为17.0%。在7.8%的患者中观察到出血事件,需要进行其他研究以明确各种血栓形成事件的重要性,并确定改善患者预后的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Nov 24 13:03:40 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900198, encodeId=bb6290019835, content=原文怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=935c5436122, createdName=ms4000001520957267, createdTime=Wed Nov 18 15:14:56 CST 2020, time=2020-11-18, status=1, ipAttribution=)]
    2020-11-19 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1698167, encodeId=82b7169816e84, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Nov 19 23:17:40 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929661, encodeId=203a19296610b, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Jun 14 02:17:40 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051621, encodeId=19572051621d9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Dec 23 17:17:40 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955517, encodeId=1d0f195551e14, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 23 17:17:40 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826649, encodeId=a04c182664900, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 03 19:17:40 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901754, encodeId=9eb8901e5494, content=在COVID-19住院患者中,VTE的总体估计合并发生率为17.0%。在7.8%的患者中观察到出血事件,需要进行其他研究以明确各种血栓形成事件的重要性,并确定改善患者预后的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Nov 24 13:03:40 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900198, encodeId=bb6290019835, content=原文怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=935c5436122, createdName=ms4000001520957267, createdTime=Wed Nov 18 15:14:56 CST 2020, time=2020-11-18, status=1, ipAttribution=)]
    2021-06-14 Smile2680
  3. [GetPortalCommentsPageByObjectIdResponse(id=1698167, encodeId=82b7169816e84, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Nov 19 23:17:40 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929661, encodeId=203a19296610b, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Jun 14 02:17:40 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051621, encodeId=19572051621d9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Dec 23 17:17:40 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955517, encodeId=1d0f195551e14, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 23 17:17:40 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826649, encodeId=a04c182664900, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 03 19:17:40 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901754, encodeId=9eb8901e5494, content=在COVID-19住院患者中,VTE的总体估计合并发生率为17.0%。在7.8%的患者中观察到出血事件,需要进行其他研究以明确各种血栓形成事件的重要性,并确定改善患者预后的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Nov 24 13:03:40 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900198, encodeId=bb6290019835, content=原文怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=935c5436122, createdName=ms4000001520957267, createdTime=Wed Nov 18 15:14:56 CST 2020, time=2020-11-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1698167, encodeId=82b7169816e84, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Nov 19 23:17:40 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929661, encodeId=203a19296610b, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Jun 14 02:17:40 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051621, encodeId=19572051621d9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Dec 23 17:17:40 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955517, encodeId=1d0f195551e14, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 23 17:17:40 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826649, encodeId=a04c182664900, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 03 19:17:40 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901754, encodeId=9eb8901e5494, content=在COVID-19住院患者中,VTE的总体估计合并发生率为17.0%。在7.8%的患者中观察到出血事件,需要进行其他研究以明确各种血栓形成事件的重要性,并确定改善患者预后的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Nov 24 13:03:40 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900198, encodeId=bb6290019835, content=原文怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=935c5436122, createdName=ms4000001520957267, createdTime=Wed Nov 18 15:14:56 CST 2020, time=2020-11-18, status=1, ipAttribution=)]
    2021-08-23 xue8602
  5. [GetPortalCommentsPageByObjectIdResponse(id=1698167, encodeId=82b7169816e84, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Nov 19 23:17:40 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929661, encodeId=203a19296610b, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Jun 14 02:17:40 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051621, encodeId=19572051621d9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Dec 23 17:17:40 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955517, encodeId=1d0f195551e14, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 23 17:17:40 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826649, encodeId=a04c182664900, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 03 19:17:40 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901754, encodeId=9eb8901e5494, content=在COVID-19住院患者中,VTE的总体估计合并发生率为17.0%。在7.8%的患者中观察到出血事件,需要进行其他研究以明确各种血栓形成事件的重要性,并确定改善患者预后的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Nov 24 13:03:40 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900198, encodeId=bb6290019835, content=原文怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=935c5436122, createdName=ms4000001520957267, createdTime=Wed Nov 18 15:14:56 CST 2020, time=2020-11-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1698167, encodeId=82b7169816e84, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Nov 19 23:17:40 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929661, encodeId=203a19296610b, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Jun 14 02:17:40 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051621, encodeId=19572051621d9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Dec 23 17:17:40 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955517, encodeId=1d0f195551e14, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 23 17:17:40 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826649, encodeId=a04c182664900, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 03 19:17:40 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901754, encodeId=9eb8901e5494, content=在COVID-19住院患者中,VTE的总体估计合并发生率为17.0%。在7.8%的患者中观察到出血事件,需要进行其他研究以明确各种血栓形成事件的重要性,并确定改善患者预后的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Nov 24 13:03:40 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900198, encodeId=bb6290019835, content=原文怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=935c5436122, createdName=ms4000001520957267, createdTime=Wed Nov 18 15:14:56 CST 2020, time=2020-11-18, status=1, ipAttribution=)]
    2020-11-24 咻凡

    在COVID-19住院患者中,VTE的总体估计合并发生率为17.0%。在7.8%的患者中观察到出血事件,需要进行其他研究以明确各种血栓形成事件的重要性,并确定改善患者预后的策略。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1698167, encodeId=82b7169816e84, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Nov 19 23:17:40 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929661, encodeId=203a19296610b, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Jun 14 02:17:40 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051621, encodeId=19572051621d9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Dec 23 17:17:40 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955517, encodeId=1d0f195551e14, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 23 17:17:40 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826649, encodeId=a04c182664900, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 03 19:17:40 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901754, encodeId=9eb8901e5494, content=在COVID-19住院患者中,VTE的总体估计合并发生率为17.0%。在7.8%的患者中观察到出血事件,需要进行其他研究以明确各种血栓形成事件的重要性,并确定改善患者预后的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Nov 24 13:03:40 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900198, encodeId=bb6290019835, content=原文怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=935c5436122, createdName=ms4000001520957267, createdTime=Wed Nov 18 15:14:56 CST 2020, time=2020-11-18, status=1, ipAttribution=)]
    2020-11-18 ms4000001520957267

    原文怎么看?

    0

相关资讯

JAMA Surg:住院前应用氨甲环酸与受伤患者死亡风险研究

对于特定的出血风险受伤患者中,住院前应用氨甲环酸可降低30天死亡率

JACC:出院后出血与急性心梗患者死亡率相关

在未经皮冠状动脉介入治疗(PCI)的急性冠脉综合征(ACS)患者中,出院后出血的长期预后影响尚不清楚。本研究的目的是根据治疗策略(PCI或非PCI)评估ACS患者出院后出血与随后死亡率之间的关系。

JACC:鱼精蛋白预防TAVR患者出血并发症的安全性和疗效

与没有逆转肝素的患者相比,给予鱼精蛋白可以降低危及生命和大出血并发症的发生率。使用鱼精蛋白不会增加卒中和心肌梗死的发病率。

Blood:新冠病毒感染者的出血和血栓栓塞风险及预测标志物

新冠病毒(COVID-19)患者的D-二聚体水平升高。早期报道提示新冠病毒感染患者有较高的静脉血栓栓塞(VTE)和弥散性血管内凝血(DIC)的概率,但无明确数据。

JAHA:抗凝房颤患者出血后新发癌症诊断分析

在接受口服抗凝治疗的AF患者中,任何胃肠道、泌尿生殖道或支气管肺部出血与新发癌症的诊断率升高有关。这些出血事件应促使对这些部位的癌症进行筛查。

Circulation:心血管疾病患者采用阿司匹林抗凝的最适持续时间

AUGUSTUS试验显示,房颤、近期发生过急性冠脉综合征和经皮冠状动脉介入治疗的患者采用阿哌沙班治疗的出血事件少于采用维生素K拮抗剂(VKA),安慰剂处理的少于服用阿司匹林的。但安慰剂组的缺血事件量明